NEW YORK (GenomeWeb) – Researchers from the West German Study Group shared updated five-year outcomes data from the PlanB study today at the 10th European Breast Cancer Conference in Amsterdam.

PlanB was initiated in 2009 as a trial comparing anthracycline-containing chemotherapy to anthracycline-free regimens in women with HER2-negative breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.